Search
Nesolicaftor
go.drugbank.com/drugs/DB15239InvestigationalNesolicaftor (PTI-428) is under investigation in clinical trial NCT03258424 (Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background
AMP-201
go.drugbank.com/drugs/DB18663ExperimentalAMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Benapenem
go.drugbank.com/drugs/DB18883Investigational(AP)). … Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (Cuti) or Acute Pyelonephritis
Minzasolmin
go.drugbank.com/drugs/DB18961InvestigationalMinzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's
AAV8-RK-RetGC
go.drugbank.com/drugs/DB32389ExperimentalAAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.
Ciluprevir
go.drugbank.com/drugs/DB05868InvestigationalThe compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.
Nemiralisib
go.drugbank.com/drugs/DB16253InvestigationalNemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary
CMLVAX100
go.drugbank.com/drugs/DB05164ExperimentalCMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia.
Cilnidipine
go.drugbank.com/drugs/DB09232InvestigationalCilnidipine is a dihydropyridine calcium antagonist. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.